Payment overview · 2025
General Payments
$1,886.85
84 reported records · 21 companies
Healthcare provider profile · identity verified
Wei Wang, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · BROOKLYN, NY · NPI 1972528032
Verified facts
What the public records show
CMS Open Payments records show Wei Wang, M.D. received $1,886.85 in general payments during 2025 across 84 reported records.
ABBVIE INC. accounted for 18.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 38 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Arexvy, Creon, Eliquis, Farxiga, Jardiance, Linzess, Nexletol, Prolia, Shingrix, Trelegy Ellipta, Zenpep.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 171 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Synthroid by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Zenpep by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Prolia by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Nexium by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 507 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 155 claims for Eliquis by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLETOL as an associated drug or biological on 24230 records involving 12642 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Nexletol by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 143 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 206 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 507 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 105 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 238 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 155 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $348.82 | 18.5% | 20 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $293.12 | 15.5% | 9 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $251.14 | 13.3% | 9 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $136.09 | 7.2% | 6 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $110.71 | 5.9% | 5 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $109.19 | 5.8% | 5 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $89.43 | 4.7% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $85.77 | 4.5% | 5 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $76.83 | 4.1% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $55.93 | 3.0% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $49.28 | 2.6% | 2 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $47.34 | 2.5% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $39.40 | 2.1% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $33.37 | 1.8% | 2 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $28.34 | 1.5% | 1 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $27.98 | 1.5% | 1 | 2025 |
| Incyte Corporation | Unresolved — no canonical attribution shown | $27.38 | 1.4% | 1 | 2025 |
| BeOne Medicines USA, Inc. | Unresolved — no canonical attribution shown | $25.16 | 1.3% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $19.63 | 1.0% | 1 | 2025 |
| Hologic Sales and Service, LLC | Unresolved — no canonical attribution shown | $16.02 | 0.8% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $15.92 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,886.85 | 84 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CREON Normalized: creon |
Drug | ABBVIE INC. | $297.24 | 18 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $293.12 | 9 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $251.14 | 9 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $204.32 | 11 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $109.19 | 5 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $89.43 | 4 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $85.01 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $76.83 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $72.52 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $51.20 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $49.28 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $38.19 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $38.19 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $38.19 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $37.22 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $33.37 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $32.24 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $28.34 | 1 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $27.98 | 1 | 2025 |
Source payment records
|
|||||
| MONJUVI Normalized: monjuvi |
Drug | Incyte Corporation | $27.38 | 1 | 2025 |
Source payment records
|
|||||
| PEMAZYRE Normalized: pemazyre |
Drug | Incyte Corporation | $27.38 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $25.65 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $25.20 | 1 | 2025 |
Source payment records
|
|||||
| BRUKINSA Normalized: brukinsa |
Drug | BeOne Medicines USA, Inc. | $25.16 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $24.74 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $24.06 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $22.19 | 1 | 2025 |
Source payment records
|
|||||
| VOWST Normalized: vowst |
Biological | Aimmune Therapeutics, Inc. | $22.14 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $19.63 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $18.84 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $18.75 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $18.71 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $18.71 | 1 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $17.21 | 1 | 2025 |
Source payment records
|
|||||
| APTIMA Normalized: aptima |
Device | Hologic Sales and Service, LLC | $16.02 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $15.92 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $15.82 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $13.91 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 238 | exact normalized | Medicare Part D |
| AREXVY arexvy |
2025 | Arexvy | 2024 | 143 | exact normalized | Medicare Part D |
| CREON creon |
2025 | Creon | 2024 | 171 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 155 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 108 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 507 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 67 | exact normalized | Medicare Part D |
| NEXLETOL nexletol |
2025 | Nexletol | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 16 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 206 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
171 | 45 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
67 | 18 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
16 | 14 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
49 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
108 | 16 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
42 | 18 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
507 | 69 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
155 | 24 |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLETOL open payments reported associated product |
CMS Open Payments — General Payments 24230 supporting records · 12642 recipient NPIs · example record 1243949989 |
Nexletol · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
143 | 142 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
206 | 160 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
507 | 69 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
105 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
238 | 235 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
155 | 24 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
16 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 2471 | 363 |
| Metformin Hcl | Metformin Hcl | 2276 | 298 |
| Amlodipine Besylate | Amlodipine Besylate | 2113 | 328 |
| Losartan Potassium | Losartan Potassium | 1945 | 272 |
| Simvastatin | Simvastatin | 1850 | 274 |
| Donepezil Hcl | Donepezil Hcl | 1309 | 211 |
| Omeprazole | Omeprazole | 1259 | 358 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1151 | 172 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 960 | 220 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 909 | 127 |
| Vascepa | Icosapent Ethyl | 905 | 183 |
| Clobetasol Propionate | Clobetasol Propionate | 876 | 266 |
| Tamsulosin Hcl | Tamsulosin Hcl | 873 | 141 |
| Diclofenac Sodium | Diclofenac Sodium | 822 | 247 |
| Mometasone Furoate | Mometasone Furoate | 816 | 177 |
| Enalapril Maleate | Enalapril Maleate | 760 | 104 |
| Ammonium Lactate | Ammonium Lactate | 728 | 201 |
| Metoprolol Succinate | Metoprolol Succinate | 693 | 98 |
| Alendronate Sodium | Alendronate Sodium | 669 | 110 |
| Allopurinol | Allopurinol | 659 | 101 |
| Meclizine Hcl | Meclizine Hcl | 648 | 260 |
| Gabapentin | Gabapentin | 638 | 138 |
| Diclofenac Epolamine | Diclofenac Epolamine | 598 | 132 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 593 | 149 |
| Azithromycin | Azithromycin | 581 | 339 |
| Glipizide | Glipizide | 578 | 84 |
| Levothyroxine Sodium | Levothyroxine Sodium | 575 | 78 |
| Fluticasone Propionate | Fluticasone Propionate | 569 | 217 |
| Zolpidem Tartrate | Zolpidem Tartrate | 569 | 218 |
| Jardiance | Empagliflozin | 507 | 69 |
| Hydrocortisone | Hydrocortisone | 505 | 215 |
| Fenofibrate | Fenofibrate,micronized | 503 | 101 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 490 | 146 |
| Pantoprazole Sodium | Pantoprazole Sodium | 449 | 109 |
| Montelukast Sodium | Montelukast Sodium | 441 | 107 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 411 | 138 |
| Famotidine | Famotidine | 397 | 92 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 393 | 84 |
| Glipizide Er | Glipizide | 350 | 45 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 349 | 58 |
| Clobetasol Emollient | Clobetasol Propionate/Emoll | 341 | 56 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 339 | 125 |
| Halobetasol Propionate | Halobetasol Propionate | 333 | 123 |
| Naproxen | Naproxen | 320 | 192 |
| Finasteride | Finasteride | 312 | 50 |
| Doxazosin Mesylate | Doxazosin Mesylate | 309 | 44 |
| Atenolol | Atenolol | 302 | 48 |
| Cromolyn Sodium | Cromolyn Sodium | 302 | 136 |
| Ibuprofen | Ibuprofen | 294 | 156 |
| Bepotastine Besilate | Bepotastine Besilate | 286 | 69 |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 270 | 31 |
| Ketoconazole | Ketoconazole | 252 | 56 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 238 | 235 |
| Hydrochlorothiazide | Hydrochlorothiazide | 233 | 54 |
| Alprazolam | Alprazolam | 229 | 44 |
| Clopidogrel | Clopidogrel Bisulfate | 224 | 34 |
| Januvia | Sitagliptin Phosphate | 213 | 31 |
| Icosapent Ethyl | Icosapent Ethyl | 210 | 120 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 206 | 160 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 186 | 124 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 180 | 128 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 179 | 96 |
| Folic Acid | Folic Acid | 177 | 32 |
| Azelastine Hcl | Azelastine Hcl | 175 | 55 |
| Cyclosporine | Cyclosporine | 175 | 39 |
| Creon | Lipase/Protease/Amylase | 171 | 45 |
| Meloxicam | Meloxicam | 163 | 69 |
| Eliquis | Apixaban | 155 | 24 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 154 | 43 |
| Metoprolol Tartrate | Metoprolol Tartrate | 154 | 23 |
| Loperamide | Loperamide Hcl | 151 | 91 |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 150 | 48 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 149 | 23 |
| Amoxicillin | Amoxicillin | 147 | 85 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 143 | 142 |
| Furosemide | Furosemide | 135 | 31 |
| Nitroglycerin | Nitroglycerin | 135 | 46 |
| Clotrimazole | Clotrimazole | 130 | 44 |
| Procto-Med Hc | Hydrocortisone | 127 | 41 |
| Oxybutynin Chloride | Oxybutynin Chloride | 125 | 26 |
| Lisinopril | Lisinopril | 122 | 18 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 121 | 92 |
| Alcohol Pads | Alcohol Antiseptic Pads | 119 | 28 |
| Sertraline Hcl | Sertraline Hcl | 119 | 22 |
| Lidocaine | Lidocaine | 118 | 39 |
| Prednisone | Prednisone | 115 | 81 |
| Rivastigmine | Rivastigmine | 113 | 19 |
| Mupirocin | Mupirocin | 109 | 56 |
| Farxiga | Dapagliflozin Propanediol | 108 | 16 |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 106 | 38 |
| Methimazole | Methimazole | 105 | 19 |
| Trulicity | Dulaglutide | 105 | 16 |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 104 | 31 |
| Restasis | Cyclosporine | 102 | 24 |
| Acarbose | Acarbose | 99 | 15 |
| Celecoxib | Celecoxib | 94 | 22 |
| Dexlansoprazole Dr | Dexlansoprazole | 88 | 22 |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 88 | 40 |
| Dicyclomine Hcl | Dicyclomine Hcl | 87 | 37 |
| Denta 5000 Plus | Fluoride (Sodium) | 86 | 21 |
| Mirtazapine | Mirtazapine | 83 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 81 | 39 |
| Baclofen | Baclofen | 78 | 38 |
| Ciprofloxacin-Dexamethasone | Ciprofloxacin Hcl/Dexameth | 78 | 38 |
| Oxycodone Hcl | Oxycodone Hcl | 78 | suppressed |
| Entecavir | Entecavir | 77 | 11 |
| Ranolazine Er | Ranolazine | 77 | 12 |
| Memantine Hcl Er | Memantine Hcl | 75 | 11 |
| Namzaric | Memantine Hcl/Donepezil Hcl | 75 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 74 | 13 |
| Ciclopirox | Ciclopirox | 73 | 23 |
| Clonazepam | Clonazepam | 72 | 15 |
| Fluocinonide | Fluocinonide | 72 | 26 |
| Ozempic | Semaglutide | 72 | 12 |
| Raloxifene Hcl | Raloxifene Hcl | 72 | 11 |
| Proctozone-Hc | Hydrocortisone | 69 | 23 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 68 | 33 |
| Fenofibrate | Fenofibrate Nanocrystallized | 67 | 13 |
| Linzess | Linaclotide | 67 | 18 |
| Trazodone Hcl | Trazodone Hcl | 67 | 20 |
| Tobradex | Tobramycin/Dexamethasone | 66 | 38 |
| Tacrolimus | Tacrolimus | 63 | suppressed |
| Potassium Chloride | Potassium Chloride | 62 | 19 |
| Sucralfate | Sucralfate | 61 | 17 |
| Nifedipine Er | Nifedipine | 59 | suppressed |
| Pure Comfort Alcohol Pad | Alcohol Antiseptic Pads | 59 | 14 |
| Breo Ellipta | Fluticasone/Vilanterol | 55 | 17 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 52 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 52 | suppressed |
| Xarelto | Rivaroxaban | 52 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 51 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 51 | 26 |
| Fluoxetine Hcl | Fluoxetine Hcl | 51 | suppressed |
| Memantine Hcl | Memantine Hcl | 51 | 11 |
| Methotrexate | Methotrexate Sodium | 51 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 51 | 26 |
| Colchicine | Colchicine | 50 | suppressed |
| Gemfibrozil | Gemfibrozil | 49 | 12 |
| Myrbetriq | Mirabegron | 49 | suppressed |
| Risperidone | Risperidone | 49 | suppressed |
| Fenofibrate | Fenofibrate | 48 | 13 |
| Olanzapine | Olanzapine | 48 | suppressed |
| Scopolamine | Scopolamine | 47 | 19 |
| Pioglitazone Hcl | Pioglitazone Hcl | 46 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 45 | suppressed |
| Glimepiride | Glimepiride | 44 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 44 | suppressed |
| Nystatin | Nystatin | 44 | 15 |
| Clindamycin Phosphate | Clindamycin Phosphate | 43 | 25 |
| Clonidine Hcl | Clonidine Hcl | 43 | 11 |
| Lansoprazole | Lansoprazole | 43 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 43 | 23 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 43 | 34 |
| Solifenacin Succinate | Solifenacin Succinate | 43 | 11 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 42 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 42 | 18 |
| Ursodiol | Ursodiol | 41 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 40 | 19 |
| Ezetimibe | Ezetimibe | 40 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 39 | 11 |
| Vemlidy | Tenofovir Alafenamide | 39 | suppressed |
| Carvedilol | Carvedilol | 38 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 38 | 27 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 37 | suppressed |
| Meloxicam | Meloxicam, Submicronized | 37 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 35 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 35 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 34 | suppressed |
| Dutasteride | Dutasteride | 34 | suppressed |
| Latanoprost | Latanoprost | 34 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 34 | 12 |
| Metronidazole | Metronidazole | 33 | 21 |
| Propranolol Hcl | Propranolol Hcl | 33 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 32 | suppressed |
| Lactulose | Lactulose | 30 | 17 |
| Spironolactone | Spironolactone | 30 | suppressed |
| Roflumilast | Roflumilast | 29 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 28 | suppressed |
| Ssd | Silver Sulfadiazine | 28 | 14 |
| Sumatriptan Succinate | Sumatriptan Succinate | 28 | 13 |
| Alcohol Swab | Alcohol Antiseptic Pads | 26 | 12 |
| Alcohol Swabs | Alcohol Antiseptic Pads | 26 | 13 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 26 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 26 | 14 |
| Valsartan | Valsartan | 26 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 25 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 25 | suppressed |
| Mesalamine | Mesalamine | 25 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 25 | suppressed |
| True Comfort Pro Alcohol Pads | Alcohol Antiseptic Pads | 25 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 24 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 24 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 24 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 23 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 23 | suppressed |
| Lorazepam | Lorazepam | 23 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 23 | 12 |
| Warfarin Sodium | Warfarin Sodium | 23 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 22 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 22 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 22 | suppressed |
| Rybelsus | Semaglutide | 22 | suppressed |
| Synthroid | Levothyroxine Sodium | 22 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 22 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 22 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 21 | 17 |
| Brilinta | Ticagrelor | 20 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 20 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 20 | suppressed |
| Nexium | Esomeprazole Magnesium | 20 | suppressed |
| Paxlovid (Eua) | Nirmatrelvir/Ritonavir | 20 | 20 |
| Probenecid | Probenecid | 20 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 20 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 19 | suppressed |
| Mupirocin | Mupirocin Calcium | 19 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 19 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 19 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 18 | suppressed |
| Cephalexin | Cephalexin | 18 | 16 |
| Nebivolol Hcl | Nebivolol Hcl | 18 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 18 | suppressed |
| Sf 5000 Plus | Fluoride (Sodium) | 18 | suppressed |
| Amantadine | Amantadine Hcl | 17 | suppressed |
| Anastrozole | Anastrozole | 17 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 17 | suppressed |
| Febuxostat | Febuxostat | 17 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 17 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 16 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 16 | 11 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 16 | suppressed |
| Entresto | Sacubitril/Valsartan | 16 | suppressed |
| Nexletol | Bempedoic Acid | 16 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 16 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 16 | 16 |
| Pilocarpine Hcl | Pilocarpine Hcl | 16 | suppressed |
| Prolia | Denosumab | 16 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 16 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 15 | 11 |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 15 | suppressed |
| Mesalamine Er | Mesalamine | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | 13 |
| Clonidine | Clonidine | 14 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Oxiconazole Nitrate | Oxiconazole Nitrate | 14 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 14 | suppressed |
| Zileuton Er | Zileuton | 14 | suppressed |
| Carbamazepine | Carbamazepine | 13 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 13 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 13 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 12 | suppressed |
| Bromocriptine Mesylate | Bromocriptine Mesylate | 12 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 12 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 12 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 12 | suppressed |
| Sodium Fluoride 5000 Plus | Fluoride (Sodium) | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Chlorzoxazone | Chlorzoxazone | 11 | suppressed |
| Dihydroergotamine Mesylate | Dihydroergotamine Mesylate | 11 | suppressed |
| Erythromycin | Erythromycin Base | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Ibu | Ibuprofen | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Propylthiouracil | Propylthiouracil | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
| Viread | Tenofovir Disoproxil Fumarate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,886.85 · 84 records | ABBVIE INC. | ABRYSVO, ACCRUFER, AIRSUPRA, APTIMA, AREXVY, Arikayce, BREZTRI, BRUKINSA, CAMZYOS, CAPLYTA, COBENFY, COMIRNATY, CREON, Cologuard Collection Kit, ELIQUIS, EVENITY, FANAPT, FARXIGA, IBSRELA, JARDIANCE, Kerendia, LINZESS, MONJUVI, MOUNJARO, NEXLETOL, NURTEC ODT, OTEZLA, PEMAZYRE, PREVNAR 20, PROLIA, REPATHA, SHINGRIX, TRELEGY ELLIPTA, VOWST, VRAYLAR, Veozah, ZENPEP, ZEPBOUND | 21 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error